期刊文献+

体外MTT法预测卵巢上皮癌化疗药敏性与体内疗效相关性的评估 被引量:4

The Evaluation of MTT Assay in vitro for Prediction of the Correlativity between the sensitivity of Chemotherapeutic Agents in vitro and the Effect in vivo on Ovarian Epithelial Carcinoma
下载PDF
导出
摘要 目的:预测卵巢上皮癌体外化疗敏感性与体内疗效的关系。方法:运用MTT法检测7种临床常用化疗药物及6种经验组合方案对卵巢上皮癌的体外抑制率进行了检测并与体内疗效结果进行比较。结果:7种药物抑制率范围为6.25%~51.43%。其中PTX为51.43%最高,TXT为20.29%,DDP为18.57%,TPT为11.63%,ADM为11.43%,GEM8.82%及Vp-166.25%敏感性最差;6种联合方案的抑制率范围在10.00%~35.00%,TPT+PTX+DDP(35.00%)及PTX+DDP(30.00%)较好,其余4种TXT+DDP(20.59%),TPT+DDP(17.65%),GEM+DDP(11.76%)及Vp-16+ADM(10.00%)均较差。本组药物抑制率与试验前是否用过化疗药无关。体内、外敏感及耐药的总符合率为72.86%(51/70),不符合率27.14%(19/70),统计学有显著性差异(P<0.05)。结论:MTT法对卵巢上皮癌的个体化治疗计划有参考价值,能在一定程度上指导临床用药。 Objective: To assess the correlation between the sensitivity of some ehemotherapeutical agents in vitro and the effective rate of clinical treatment. Methods: Seven chemotherapeutieal agents and 6 combined regimens were used to test the inhibition ratio for 70 cases with ovarian epithelial carcinoma using MTT assay in vitro. Results: The effective rates for the agents and combined regimens were 6.25%-51.43% and 10.00%-35.00%, respectively in 7 ehemotherapeutical agents and 6 combined regimens, such as DTX (51.45%), TXT (20.29%), DDP (18.57%), TPT (11.63%), ADM (11.43%) and GEM(8.82%), as well as Vp16 (6.25%). The DTX(51.45%) was the most sensitive agent for ovarian epithelial carcinoma eompared with other 6 agents, especially the last 4, with a statistical significance (P〈0.05) and TDT+DTX+DDP(35.00%), 8DTX+DDP(30.00%) as well as 4 others, TXT+DDP (20.59%) TDT+DDP (17.65%); GEM+DDP (11.76%), Vp16+ADM (10.00%). In the study, there was no correlation between the pharmaceutieal inhibition ratio and the fact whether or not the drug has been used. The in vivo, sensitive and drug-fast coincident rate was 72.86% (51/70) and the discrepancy was 27.14%(19/ 70). There was a statistieal significance (P〈0.05) between the overall eoincidence and the discrepancy. Conclusion: The MTT assay in vitro has a referenced value for the individualized regimens on ovarian epithelioma and can, to some extent, direct the clinieal medication.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2006年第9期521-523,526,共4页 Chinese Journal of Clinical Oncology
关键词 卵巢上皮癌 化学疗法 MTT法 Ovarian epithelial carcinoma Chemotherapy MTT assay
  • 相关文献

参考文献8

二级参考文献16

  • 1[1]Sevin BU, Peng ZL, Perras JP, et al. Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing [J]. Gynecol Oncol, 1988,31: 191 -204.
  • 2[2]Nguyen HN, Sevin BU, Averette HE, et al. Comparative evaluation of single and combination chemotherapy in uterine cancer cell lines[J]. Gyneco Oncol, 1991, 42:227 -232.
  • 3[3]Ten Bokkel Huinink, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer [J]. J Clin Oncol, 1997, 15(6): 2183 -2193.
  • 4[4]Gore M, ten Bokkel Huinink W, Carmichael J, et al. Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer [J]. J Clin Oncol, 2001,19(7): 1893 - 1900.
  • 5[5]Sauer R, Heuser A. Topoisomerase I inhibitor with potential radiosensitizing effect [J]. Strahlenther Onkol, 1997, 173(3):125 - 130.
  • 6阚秀,乳腺癌临床病理学,1993年,73页
  • 7宋三泰,新药与临床,1988年,7卷,65页
  • 8汤仲明,中国临床药理学杂志,1988年,4卷,1页
  • 9徐建明,中华肿瘤杂志,1995年,17卷,100页
  • 10徐建明,国外医学.临床生物化学与检验学分册,1994年,6卷,249页

共引文献59

同被引文献50

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部